Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

• ClinicalTrials.gov Identifier: NCT05668754
• Recruitment Status: Active, not recruiting
• First Posted: December 30, 2022
• Last Update Posted: January 9, 2024
• Sponsor: Zevra Therapeutics
• Collaborator: Rho, Inc.
• Information provided by (Responsible Party): Zevra Therapeutics

Tracking Information

• First Submitted Date: December 19, 2022
• First Posted Date: December 30, 2022
• Last Update Posted Date: January 9, 2024
• Actual Study Start Date: December 28, 2022
• Estimated Primary Completion Date: June 30, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 29, 2022)

• Safety parameters - TEAEs [ Time Frame: Time Frame: Start of OLTP to end of DBWP (7 weeks) ]
  Type and frequency of Treatment-Emergent Adverse Events
• Safety parameter - Heart Rate [ Time Frame: Time Frame: Start of OLTP to end of DBWP (7 weeks) ]
  Change from baseline in heart rate (beats/minute).
• Safety parameter - Blood Pressure [ Time Frame: Time Frame: Start of OLTP to end of DBWP (7 weeks) ]
  Change from baseline in blood pressure (mmHg).
• Safety parameter - Laboratory Tests [ Time Frame: Time Frame: Start of OLTP to end of DBWP (7 weeks) ]
  Clinical significant change from baseline in clinical laboratory tests.
• Safety parameter - ECG [ Time Frame: Time Frame: Start of OLTP to end of DBWP (7 weeks) ]
  Clinical significant change from baseline in electrocardiogram (ECG).
• Safety parameter - PSQI [ Time Frame: Time Frame: Start of OLTP to end of DBWP (7 weeks) ]
  Change from baseline in Pittsburg Sleep Quality Index Question #6. Sleep quality score ranging from very good (0) to very bad (4).

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: December 29, 2022)

• Change from baseline in Epworth Sleepiness Scale (ESS) score [ Time Frame: Start to end of DBWP (2 weeks) ]
  Scores level of daytime sleepiness ranging from 0 to 24, with a higher score indicating worsened sleepiness
• Change from baseline in Brain Fog score [ Time Frame: Time Frame: Start to end of DBWP (2 weeks) ]
  Queries for frequency, severity, and symptoms of cognitive impairment in the last week.
• Percentage of participants with increase (worsening) of 2 points or more from baseline in the Clinical Global Impression of Severity (CGI-S) [ Time Frame: Start to end of DBWP (2 weeks) ]
  Clinician-reported level of illness.
• Percentage of participants with increase (worsening) of 2 points or more baseline in the Patient Global Impression of Severity (PGI-S). [ Time Frame: Start to end of DBWP (2 weeks) ]
  Patient-reported level of illness.
• Change from baseline in Total Score of the Idiopathic Hypersomnia Severity Hypersomnia Scale (IHSS) [ Time Frame: Start to end of DBWP (2 weeks) ]
  Patient-reported questionnaire assessing the severity of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. The total score ranges from 0 to 50, with higher scores indicating more severe symptoms.
• Change from baseline in Modified Karolinska Sleepiness Scale in the morning and late afternoon. [ Time Frame: Start to end of DBWP (2 weeks) ]
  Patient-reported at-the-moment sleepiness, ranging from 1 (extremely alert) to 10 (extremely sleepy, can't keep awake).
• Change from baseline in Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) total scores for depression, fatigue, and social functioning. [ Time Frame: Start to end of DBWP (2 weeks) ]
  Queries functioning and well-being in the last week.
• Change from baseline in the Patient-Reported Wakefulness Questionnaire (ZOGIM-A) total scores. [ Time Frame: Start to end of DBWP (2 weeks) ]
  Queries alertness over the course of the day.
• Change from baseline in the Sleep Inertia Visual Analog Scale (SIVAS) score. [ Time Frame: Start to end of DBWP (2 weeks) ]
  Patient-reported measure of the difficulty of waking up in the morning, ranging from 0 (very easy) to 100 (very difficult)

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
• Official Title: A Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Determine the Safety and Efficacy of Oral SDX in Patients With Idiopathic Hypersomnia (IH)
• Brief Summary: This is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).

Detailed Description

SDX is a prodrug of dexmethylphenidate (d-MPH). SDX behaves as a prototypical prodrug that is devoid of pharmacological effects until metabolized to active d-MPH. Central nervous system (CNS) stimulants, including d-MPH products, are being used off-label by patients with IH. The potential advantage of SDX-derived d-MPH is its unique PK profile with rising d-MPH plasma concentrations at approximately 3 hours postdose followed by a broad peak from approximately 8 to 12 hours postdose (without sharp exposure spikes), and a gradual decline after the peak.

The optimal dose of SDX will be determined for each participant by titration based on individual tolerability and response during the 5-week SDX-only Open-Label Titration period (OLTP), after which 2/3 of the participants will continue to receive SDX and 1/3 of the participants will receive placebo (withdrawal design) in the 2-week Double-Blind Withdrawal Period (DBWP).

The study will evaluate safety (primary endpoint), efficacy and PK in patients with IH after daily oral administration of SDX either once per day in the evening (qd pm) or twice per day (morning and evening: bid). The study is expected to inform about the optimal SDX dose range and the best dose regimen (nighttime dosing or twice-per-day) for further studies in patients with IH and narcolepsy. The evening dosing regimen (just before bedtime) is of interest since there is little or no exposure to d-MPH for the first several hours post-dose and the mean peak d-MPH concentration occurs at 10-12 hours post-dose (ie, in the morning after a nighttime dose).

• Study Type: Interventional
• Study Phase: Phase 2

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Phase 2, placebo-controlled, double-blind, randomized withdrawal study to determine the safety and efficacy of oral SDX in patients with Idiopathic Hypersomnia (IH).

Masking: Double (Participant, Investigator)
Masking Description:

Open-Label Titration Period with a Double-Blind Withdrawal Period

Primary Purpose: Treatment

• Condition: Idiopathic Hypersomnia

Intervention

• Drug: Serdexmethylphenidate
  Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
  Other Name: SDX
• Other: Placebo
  Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.

Study Arms

• Experimental: Experimental: SDX
  SDX capsules at the optimized daily dose, once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
  Intervention: Drug: Serdexmethylphenidate
• Placebo Comparator: Active Comparator
  Placebo capsules once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
  Interventions:

  • Drug: Serdexmethylphenidate
  • Other: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: December 29, 2022): 48
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: June 30, 2024
• Estimated Primary Completion Date: June 30, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. At least 18 years of age at the time of consent
2. Body Mass Index (BMI) ≤35 kg/m2
3. Documented primary diagnosis of IH according to the International Classification of Sleep Disorders (ICSD-3) criteria
4. At the Screening Visit and Baseline Visit (start of OLTP), Epworth Sleepiness Scale (ESS) scores ≥11
5. Average nightly Total Sleep Time (TST) of ≥7 hours, per subject history and confirmed during screening.
6. Subject must be in general good health defined as the absence of any clinically relevant abnormalities as determined by the Investigator based on physical and neurological examinations, vital signs, ECGs, medical history, and clinical laboratory values (hematology, chemistry, and urinalysis) at Screening.
7. If currently treated with nicotine replacement therapy, must have been taking the same regimen and dose for at least 2 months prior to screening and must agree to take the same dose during the study.
8. Have used a medically acceptable method of contraception for at least 2 months prior to the first dose of study drug and consent to use a medically acceptable method of contraception from the first dose of study drug, throughout the entire study period, and for 90 days after the last dose of study drug.

Exclusion Criteria

1. Hypersomnia due to another medical, behavioral, or psychiatric disorder condition (eg, narcolepsy, depression disorders, multiple sclerosis, Parkinson's disease, stroke).
2. Clinically significant sleep-related breathing disorders, including sleep apnea, treatment with Continuous Positive Airway Pressure (CPAP) therapy, Obstructive Apnea Hypopnea Index (AHI) >15 episodes per hour, or hypoventilation.
3. Clinically significant parasomnias (eg, sleep walking, rapid eye movement [REM] sleep behavior disorder, etc).
4. Periodic Limb Movement Disorder (PLMD) Arousal Index (PLMA-I) >15 during Screening PSG, a historical diagnosis of PLMD (last 10 years), or a PLMD diagnosis older than 10 years with current (last 60 days) treatment or symptoms of rhythmic movements involving one or both legs during sleep.
5. Occupation requiring nighttime shift work or variable shift work with early work start times (before 6 AM), if this occurs more than once per week.
6. Planned travel during the study that includes more than 3 time zones, or planned travel that includes 3 time zones on more than 2 occasions during the study.
7. Going to sleep for the night later than 1 AM at a frequency of more than once per week.
8. Current or past (within 1 year) major depressive episode according to DSM-5 criteria.
9. Any history of attempted suicide (lifetime) or clinically significant suicidal ideation, in the opinion of the Investigator, based on the C-SSRS assessment at Screening.
10. Any clinically significant unstable medical abnormality, chronic disease (eg, asthma or diabetes), or a history of a clinically significant abnormality of the cardiovascular, central nervous system,
11. Any of the following out-of-range vital signs at Screening: systolic blood pressure outside 90-145 mmHg; diastolic blood pressure outside 50-90 mmHg; resting heart rate outside 40-100 beats per minute.

12. History or presence of abnormal ECGs, which in the Investigator's opinion is clinically significant, including the following:

    1. ECG findings of ischemia or infarct
    2. Complete bundle branch blocks
    3. Symptomatic arrhythmias as ventricular arrhythmias (non- sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions), bundle branch block, axis deviation, or abnormal or any predominantly non-sinus- conducted rhythm.
    4. QTcF >450 msec for males or >470 msec for females, on Screening ECG.
    5. PR interval outside the range of 120 to 220 msec on Screening ECG
13. Estimated glomerular filtration rate (GFR) at Screening <60 mL/min/1.73 m2.
14. Malignant neoplastic disease requiring therapy within 2 years prior to Screening or during the study, or clinically relevant as judged by the Investigator.
15. Uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal (ULN) for the reference laboratory at Screening.
16. Laboratory value for aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x upper limits of normal (ULN).
17. Excessive caffeine use during the 10 days prior to first dose of study drug or anticipated excessive use defined as >600 mg/day of caffeine during the treatment periods of the study.
18. Treatment or planned treatment with prohibited medications (including medications that may affect daytime sleepiness and nighttime sleep) or unwilling to refrain from any prohibited medications. Treatment must have been discontinued 14 days or 5 half-lives, whichever is longer, prior to the first dose of study medication (and at least 30 days for sedating antidepressants; at least 14 days for CNS stimulants).
19. Current or past (within 12 months prior to Screening) substance use disorder (including alcohol and psychoactive cannabinoids) according to DSM-5 criteria; current or past history of substance abuse treatment (including alcohol), or unwilling to refrain from substance use (including alcohol) during the study.
20. Nicotine dependence that has an effect on sleep (eg, a subject who routinely awakens at night to smoke).
21. Evidence of substance or alcohol use or has a positive urine or breath alcohol or positive urine drug screen at Screening.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT05668754
• Other Study ID Numbers: KP1077.D01
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Zevra Therapeutics
• Original Responsible Party: Same as current
• Current Study Sponsor: Zevra Therapeutics
• Original Study Sponsor: Same as current
• Collaborators: Rho, Inc.

Investigators

• Principal Investigator: Christopher Drake, PhD; Investigator

• PRS Account: Zevra Therapeutics
• Verification Date: January 2024